Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P83 | ISIN: CH1384053976 | Ticker-Symbol:
NASDAQ
06.06.25 | 16:45
2,255 US-Dollar
+6,37 % +0,135
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NLS PHARMACEUTICS LTD Chart 1 Jahr
5-Tage-Chart
NLS PHARMACEUTICS LTD 5-Tage-Chart

Aktuelle News zur NLS PHARMACEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.05.NLS Pharmaceutics präsentiert Mazindol-Studie auf ASCP-Tagung-
21.05.NLS Pharmaceutics to present Mazindol study at ASCP Meeting2
16.05.NLS Pharmaceutics Ltd. - 20-F, Annual and transition report of foreign private issuers1
05.05.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
24.04.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
15.04.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
15.04.NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models165Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value...
► Artikel lesen
NLS PHARMACEUTICS Aktie jetzt für 0€ handeln
31.03.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer-
31.03.NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement364The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage...
► Artikel lesen
10.03.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
10.03.NLS Pharmaceutics kündigt Fusion mit Kadimastem an2
27.02.NLS Pharmaceutics reports progress in narcolepsy treatment1
27.02.NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform188ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon...
► Artikel lesen
25.02.NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment235Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel...
► Artikel lesen
25.02.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer-
10.02.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
05.02.NLS Pharmaceutics files to sell 645.2K shares for holders1
31.01.NLS Pharmaceutics Stock Rises 29% Following Merger Announcement With Kadimastem-
31.01.What's Going On With NLS Pharmaceutics Stock Friday?1
31.01.Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics894ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1